Citi analyst Yigal Nochomovitz yesterday morning downgraded Mirati Therapeutics to Neutral from Buy with a price target of $53, down from $121. The reported adagrasib plus pembrolizumab data are not clearly superior to the benchmarks cited by management, said the analyst, who sees the Phase 3 trials as "high-risk." Nochomovitz’s impression from speaking with Mirati last week is that an acquisition is not imminent. And with the new data, "M&A is appearing less likely, plus there are limited near-term events that could drive upside," Nochomovitz told investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics price target lowered to $61 from $100 at BofA
- Mirati Therapeutics downgraded to Neutral from Overweight at JPMorgan
- Mirati Therapeutics price target lowered to $60 from $85 at Oppenheimer
- B. Riley biotechnology analysts to hold an analyst/industry conference call
- Mirati Therapeutics downgraded to Market Perform from Outperform at BMO Capital